Diabetes newco Islexa launched

The U.K.'s Cell and Gene Therapy Catapult (CGT) and University of Aberdeen formed newco Islexa Ltd. to develop cell therapy technology to treat Type I diabetes.

The technology would enable reprogramming of donor pancreatic tissue into functional islets, expanding the number of patients who can receive islet cell transplants from donated pancreas tissue. The approach addresses a key obstacle for islet cell transplantation, the shortage of donor cells (see BioCentury Innovations, Jan. 7). ...